AI-ACCELERATED DRUG DISCOVERY

The future of drug design

Receptor.AI is a next-generation TechBio company advancing a multiplatform ecosystem featuring advanced AI-powered platforms for small molecule and peptide design.

The future of drug design

Who we are?

Receptor.AI is a pioneering TechBio company transforming drug discovery through a validated, AI-powered multiplatform ecosystem. We specialize in developing advanced platforms that address the most complex and previously "undruggable" targets with first-in-class therapeutic modalities, ensuring precision and innovation at every step.

We are committed to making early-stage drug discovery significantly faster and more cost-effective, empowering researchers to achieve breakthroughs with confidence. Our ecosystem drives innovations that directly impact healthcare by targeting diseases with high unmet needs. Working on diverse, high-impact drug discovery projects, we rigorously test and refine our platforms, ensuring we deliver state-of-the-art capabilities informed by unparalleled industry experience.

Receptor.AI is a team of seasoned scientists, engineers, and industry experts dedicated to revolutionizing drug discovery with combined expertise and shared vision. We are strongly confident that technological innovation in drug design will radically change our civilization in the near future.

Our Timeline

Company Incorporation
Our tech-bio company was founded in Kyiv with a team of 15 experts specializing in medicinal chemistry and AI, aiming to develop a best-in-class AI-driven drug discovery platform.
Q1 2021
Validation of Platform MVP
We completed our first MVP case study, focusing on targeting BRD4 and SIRT1 proteins in collaboration with a leading CRO.
Q3 2021
Leading AI Models for Drug Discovery
We developed the second generation of AI models, including our core semi-ligand-based model, 3DProtDTA, and a Multitask ADMET model with 35 parameters.
Q4 2021
Platform Development
We launched the first version of our SaaS platform, establishing the foundation for scalable drug discovery solutions.
Q2 2022:
Commercial Milestone
We secured our first commercial project, marking a significant milestone in our market entry.
Q3 2022
Relocation of Headquarters
Our headquarters were relocated to London, with key employees and R&D operations moving to Central Europe.
Q3 2022
Lead Optimization Initiatives
We initiated our first lead optimization stage project, further enhancing our track record and expertise.
Q4 2022
Development of Selectivity Platform
We successfully developed our selectivity platform, expanding our capabilities in targeting difficult-to-drug proteins.
Q4 2022
Achieving IND-Stage
We completed our first IND-stage project, focusing on developing lipid formulations for TLR agonists.
Q1 2023
Customer Success and Strategic Partnerships
We entered our first partnership with a mid-sized pharmaceutical company and reached a total of 15 commercial drug discovery projects.
Q3 2023
Best AI docking outperforming AlphaFold
We developed ArtiDock, a best-in-class AI docking model that outperforms all conventional and AI docking techniques, including AlphaFold.
Q4 2023
Partnership with Nvidia and Peptide Drug Discovery
We partnered with Nvidia to enhance our generative AI capabilities and launched our first medium pharma project focused on peptide drug discovery.
Q1 2024
Strategic Big Pharma Partnership
We established a key partnership with a major pharmaceutical company, concentrating on membrane mitochondrial kinases.
Q2 2024
Innovations in PPIs and Induced Proximity
We developed a template-agnostic model for PPI targeting and integrated it into workflows for designing induced proximity compounds.
Q3 2024
Operational Excellence
We initiated 40 drug discovery projects, achieving an 86% success rate for completed projects.
Q3 2024
Headquatering in the US
We expanded into the US market by opening a headquarters in Boston and growing our team to 35 members and extending our advisors board.
Q3 2024
Our team
The Receptor.AI team is made up of more than 30 specialists with expertise in AI, computational chemistry, and biology. Building on its Ukrainian roots, the company, based in London and Boston, extends its reach and enhances its capabilities within the global pharmaceutical sector through its R&D facility in Germany.
Dr. Alan Nafiev

Dr. Alan Nafiev

Chief Executive Officer,
Co-founder

Ph.D. holder in Data Science with expertise
in leading AI-driven drug discovery projects. He specializes in designing cloud systems for life sciences, particularly focusing on AI-powered workflows. With a strong background in B2B start-ups, he brings valuable experience to the intersection of data science and the life sciences industry.

Dr. Sergii Starosyla

Dr. Sergii Starosyla

Chief Technical Officer,
Co-founder

PhD in Molecular Biology with over 15 years of experience in drug discovery and scientific software development. Medicinal chemist, expert in development of machine-learning models, algorithms for pharmacophore modelling and molecular docking. Author of number of patented anticancer and anti-microbic biologically active compounds.

Dr. Semen Yesylevskyy

Dr. Semen Yesylevskyy

Chief Scientific Officer,

Co-founder

PhD, Dr.Sci. in biophysics. 20+ years of experience in molecular modelling, computational drug discovery and scientific software development. Author of unique techniques and algorithms in simulations of curved and asymmetric lipid membranes and assessment of drug-membrane interactions.

Dr. Volodymyr Bdzhola

Dr. Volodymyr Bdzhola

Head of Medicinal Chemistry

PhD in Chemistry with 25 years of research experience, a pivotal member of the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, currently serving as a Senior Research Scientist and Deputy Head of the Department of Medicinal Chemistry. Contributed to over 65 scientific publications, showcasing his extensive research in the field.

Askar Kuchumov

Head of Business Development

Ph.D. in Biochemistry and Molecular Biology with 15+ years of experience in biotech business development and venture capital. Co-founder of several oncology startups, successfully advancing two first-in-class programs from discovery to Phase II clinical trials. Co-author in 20+ peer-reviewed publications, and 2 patent applications.

Dr. Nicolas Babault

Scientific Advisor: Drug Discovery

PhD in Biophysics & Biochemistry with 15+ years of R&D experience across Industry and Academia, spanning from experimental validation to leadership roles. Extensive expertise in developing and optimizing drug discovery platforms, with deep knowledge in hit discovery and lead optimization for small molecules, peptides, and oligonucleotides.

Dr. Rajiah Aldrin Denny

Scientific Advisor: Drug Discovery

Ph.D in Computational Sciences with 25+ years experience in the industry, including Pfizer and Biogen. Delivered 8 new chemical entities (NCEs) to the clinic/FIH assessment. Worked on over 60+ lead identification & optimization projects covering small molecules, peptides, ADCs, and degraders in a variety of indications.

Dr. Elena Brin

Dr. Elena Brin

Scientific Advisor: Pharmacology

PhD in Pharmacology with 20+ years of R&D experience in Biotech and Big Pharma. Specializes in oncology drug discovery, including targeted and immuno-oncology therapies. Proven leadership guiding teams from early discovery to IND submissions, contributing to approved drugs. Strong record in in vitro and in vivo study design and clinical-stage assay development.

Prof. Kevin Burgess

Scientific Advisor: PPI Modulators

Renowned Rachal Professor of Chemistry at Texas A&M, who has made significant contributions to the fields of medicinal and combinatorial chemistry. He applies his expertise in peptido-mimetics, hybrid-peptides and PPI targeting.

Prof. Christophe Ramseyer

Scientific Advisor: Membrane Biophysics

PhD, Professor of Physics with 20+ years of experience  in quantum chemistry and computational drug design. An expert in simulating interactions of theragnostic nanoparticles with the cell membrane.

Prof. Mikhail Bogdanov

Scientific Advisor: Membrane Molecular Biology

PhD, Professor of Biochemistry and Molecular Biology at University of Texas Medical School with 30+ years of experience in experimental studies of lipid membranes and membrane proteins. An expert in design and assessment of membrane targeting compounds.

Dr. Yaroslav Bilokin

Scientific Advisor: Chemistry

PhD in Chemistry with 30+ years in medicinal and synthetic organic chemistry. Executive Director at OTAVA Ltd. with numerous patents and peer-reviewed publications. Combines expertise and leadership to tackle complex chemistry problems and lead innovative projects.

Dr. Andrew Golub

Scientific Advisor: CADD

PhD in Molecular Biology with 20+ years in Industry and Academia, specializing in CADD, computational chemistry, and cheminformatics. Expert in protein structure analysis, drug mechanisms, and therapeutic design. Co-author of multiple scientific papers and patents.

Roman Stratiichuk

Roman Stratiichuk

AI Drug Discovery
Project Manager

Leonid Popryho

Leonid Popryho

Lead AI Engineer

Taras Voitsitskyi

Taras Voitsitskyi

AI Engineer
Computational Chemistry

Ihor Koleiev

Ihor Koleiev

Scientist
Medicinal Chemist

Roman Zhytar

Roman Zhytar

AI Platform Developer

Zakhar Ostrovsky

Zakhar Ostrovsky

AI Solutions Developer
for Drug Discovery

Volodymyr Vozniak

Volodymyr Vozniak

AI Solutions Developer
for Drug Discovery

Pavlo Henitsoi

Pavlo Henitsoi

Drug Discovery
Platform Developer

Yana Shevchenko

Yana Shevchenko

Quality Assurance Engineer

Ivan Khorpachov

Ivan Khorpachov

AI Drug Discovery
Cloud Engineer

Vladyslav Husak

Alena Nalbat

Research Scientist

Myroslav Uiazdovskyi

Nazar Shevchuk

Medicinal Chemist

Ivan Khorpachov

Aleksandr Al-Sayed

Platform Operations Manager

Yana Shevchenko

Hlib Kholodulkin

Business Administration Manager

Vladyslav Husak

Vladyslav Husak

Platform Solutions Manager

Myroslav Uiazdovskyi

Myroslav Uiazdovskyi

BD Executive, 

AI-Enabled Therapeutics

Tetiana Skakun

Marketing Operations
Specialist

Anastasiia Vituk

TechBio Sales
Associate

 Sasha Korogodski

Project Execution Manager

Latest Updates

Our Locations

Headquarters

Ground floor-20,
United Kingdom,
20-22 Wenlock Road,
London N1 7GU

R&D facility

4th floor,
Experimentelle Fabrik,
Germany, Sandtorstraße 23,
39106 Magdeburg

US Office

100 Cambridgepark Dr
Cambridge, MA 02140

Contact us

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.